<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FOSCARNET</span><br/>(fos'car-net)<br/><span class="topboxtradename">Foscavir<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>24 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits the replication of all known herpes viruses in vitro.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts against cytomegalovirus (CMV), herpes simplex virus types 1 and 2 (HSV-1, HSV-2), human herpesvirus 6 (HHV-6), Epstein-Barr
         virus (EBV), and varicella-zoster virus (VZV).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>CMV retinitis, mucocutaneous HSV, acyclovir-resistant HSV in immunocompromised patients.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Other CMV infections, herpes zoster infections in AIDS patients.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to foscarnet.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Kidney function impairment, mineral and electrolyte imbalances, seizures, older adults; pregnancy (category C), lactation.
         Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">CMV Retinitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Induction</span> 60 mg/kg infused over 1 h q8h for 23 wk; induction may be repeated if relapse occurs during maintenance therapy <span class="rdroute">Alternate Induction Therapies</span> 100 mg/kg q12h for 23 wk or 2030 mg/kg infused over 30 min followed by a continuous infusion of 180230 mg/kg/d
               for 23 wk <span class="rdroute">Maintenance Dose</span> 90120 mg/kg/d infused over 2 h<br/><br/><span class="indicationtitle">Herpes Simplex Infections in AIDS</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4060 mg/kg q8h for 23 wk, may be followed by 50 mg/kg/d for 57 d/wk for up to 15 wk<br/><br/><span class="indicationtitle">Acyclovir-Resistant HSV in Immunocompromised Patients</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 40 mg/kg q812h for up to 3 wk or until lesions heal<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>See package insert<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li> 				Note: Dose must be adjusted for renal insufficiency. See package insert for specific dosing adjustment. 			</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span> Given undiluted (24 mg/mL) through a central line. For peripheral infusion, dilute to 12 mg/mL with D5W or NS. Do not give
                  other IV solution or drug through the same catheter with foscarnet.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  Give at a constant rate not to exceed 1 mg/kg/min over the specified period of infusion with an infusion pump. Do not increase
                  the rate of infusion or shorten the specified interval between doses. Use prepared IV solutions within 24 h. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Ringer's lactate,</b> <b>acyclovir,</b> <b>amphotericin B,</b> <b>calcium,</b> <b>co-trimoxazole,</b> <b>diazepam,</b> <b>digoxin,</b> <b>diphenhydramine,</b> <b>dobutamine,</b> <b>droperidol,</b> <b>ganciclovir,</b> <b>haloperidol,</b> <b>leucovorin,</b> <b>lorazepam,</b> <b>midazolam,</b> <b>pentamidine,</b> <b>phenytoin,</b> <b>prochlorperazine,</b> <b>promethazine,</b> <b>trimetrexate,</b> <b>vancomycin.</b> <span class="incompattype">Y-site:</span> <b>Acyclovir,</b> <b>amphotericin B,</b> <b>calcium,</b> <b>co-trimoxazole,</b> <b>diazepam,</b> <b>digoxin,</b> <b>diphenhydramine,</b> <b>dobutamine,</b> <b>droperidol,</b> <b>ganciclovir,</b> <b>haloperidol,</b> <b>leucovorin,</b> <b>lorazepam,</b> <b>midazolam,</b> <b>pentamidine,</b> <b>phenytoin,</b> <b>prochlorperazine,</b> <b>promethazine,</b> <b>trimetrexate,</b> <b>vancomycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Prehydrate and continue daily hydration with 2.5 L of NS to reduce nephrotoxicity.</li>
</ul>
<ul>
<li>Store according to manufacturer's directions.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Thrombophlebitis if infused through a peripheral vein. <span class="typehead">CNS:</span> Tremor, muscle twitching, headache, weakness, fatigue, confusion, anxiety. <span class="typehead">Endocrine:</span> <span class="speceff-common">Hyperphosphatemia,</span> hypophosphatemia, hypocalcemia. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead">Urogenital:</span> Penile ulceration. <span class="typehead">Hematologic:</span> <span class="speceff-common">Anemia,</span> leukopenia, thrombocytopenia. <span class="typehead">Renal:</span> <span class="speceff-both">Nephrotoxicity</span> (acute renal failure, tubular necrosis). <span class="typehead">Skin:</span> Fixed drug eruption, rash. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause increase or decrease in serum <span class="alt">calcium,</span> <span class="alt">phosphorus,</span> and <span class="alt">magnesium.</span> Decreases <span class="alt">Hct</span> and <span class="alt">Hgb.</span> Increased serum <span class="alt">creatinine.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">aminoglycosides</span>, <b>amphotericin B,</b> <b>vancomycin</b> may increase risk of nephrotoxicity. <b>Etidronate,</b> <b>pamidronate,</b> <b>pentamidine (IV)</b> may exacerbate hypocalcemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 37 d. <span class="typehead">Duration:</span> Relapse usually occurs 34 wk after end of therapy. <span class="typehead">Distribution:</span> 328% of dose may be deposited in bone; variable penetration into CSF; crosses placenta; distributed into breast
      milk. <span class="typehead">Metabolism:</span> Does not appear to be metabolized. <span class="typehead">Elimination:</span> 7394% excreted in urine. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for cardiac arrhythmias, especially in presence of known cardiac abnormalities.</li>
<li>Lab tests: Periodic CBC, serum electrolytes, serum creatinine, and creatinine clearance throughout therapy.</li>
<li>Monitor serum creatinine and creatinine clearance values. Drug dose will be decreased in response to decreased clearance.</li>
<li>Monitor for electrolyte imbalances.</li>
<li>Monitor for seizures and take appropriate precautions.</li>
<li>Question patients regarding local irritation of the penile or vulvovaginal epithelium. If either occurs, increase hydration
            and better personal hygiene.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report perioral tingling, numbness, and paresthesia to physician immediately.</li>
<li>Understand that drug is not a cure for CMV retinitis; regular ophthalmologic exams are necessary.</li>
<li> 							Note: Good hydration is important to maintain adequate output of urine. 						</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>